- Home
- NDMO vs CRMD Comparison
NDMO vs CRMD Comparison
Compare NDMO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.2M | 626.0M |
| IPO Year | 2019 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NDMO | CRMD |
|---|---|---|
| Price | $10.41 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 107.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.95 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $9.57 | $6.13 |
| 52 Week High | $10.82 | $14.96 |
Technical Indicators
Market Signals| Indicator | NDMO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 36.31 |
| Support Level | $10.25 | $7.05 |
| Resistance Level | $10.47 | $9.01 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 84.21 | 4.68 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.